A single-institution study examining cutaneous and non-cutaneous melanomas treated with nivolumab

J Eur Acad Dermatol Venereol. 2016 Dec;30(12):e227-e229. doi: 10.1111/jdv.13561. Epub 2016 Feb 3.

Authors

K Imafuku¹, K Yoshino¹, K Ishiwata¹, S Otobe¹, S Tsuboi¹, K Ohara¹, H Hata²

Affiliations

¹ Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
² Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

PMID: 26841210
DOI: 10.1111/jdv.13561

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Female
Humans
Male
Melanoma / drug therapy*
Middle Aged
Nivolumab
Skin Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab